Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.45 |
| ▸ | FADS1 | O60427 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 5/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 5/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | ITK | Q08881 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5071848 | 0.84 | CSNK2A1 (0.47) | TRPA1GRM4FADS1KDRAURKA | |
| SCHEMBL13639119 | 0.80 | TRPA1 (0.50) | TRPA1GRM4FADS1ADRA2AAURKA | |
| SCHEMBL13636063 | 0.78 | GRM4 (0.52) | TRPA1GRM4FADS1KDREGFR | |
| SCHEMBL12510675 | 0.74 | TRPA1 (0.49) | TRPA1GRM4FADS1ADRA2AAURKA | |
| SCHEMBL12510676 | 0.74 | TRPA1 (0.54) | TRPA1GRM4FADS1ADRA2A | |
| SCHEMBL802356 | 0.71 | TRPA1 (0.47) | TRPA1GRM4FADS1ADRA2AAURKA | |
| SCHEMBL29882003 | 0.69 | TRPA1 (0.75) | TRPA1GRM4FADS1ADRA2AAURKA | |
| SCHEMBL4741513 | 0.69 | TRPA1 (0.75) | TRPA1GRM4FADS1ADRA2AAURKA | |
| SCHEMBL802368 | 0.68 | TRPA1 (0.47) | TRPA1GRM4FADS1ADRA2AAURKA | |
| SCHEMBL801729 | 0.68 | TRPA1 (0.41) | TRPA1GRM4FADS1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304414-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-06 | — | — | US | disclosed |
| US-20080287444-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-11-20 | — | — | US | disclosed |
| US-7427681-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287444-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | AURKC, AURKA, CDK3 | TRPA1 4743/4885GRM4 4721/4885FADS1 2083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.